Atea Pharmaceuticals Inc
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company … Read more
Atea Pharmaceuticals Inc (AVIR) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.102x
Based on the latest financial reports, Atea Pharmaceuticals Inc (AVIR) has a cash flow conversion efficiency ratio of -0.102x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-28.22 Million) by net assets ($275.43 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Atea Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Atea Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Atea Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Atea Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ShenZhen V&T Technologies Co Ltd
SHE:300484
|
-0.010x |
|
Jiangsu Libert Inc
SHG:605167
|
0.005x |
|
American Business Bk
OTCQX:AMBZ
|
N/A |
|
Wuestenrot & Wuerttembergische AG
LSE:0GJN
|
-0.066x |
|
Willis Lease Finance Corporation
NASDAQ:WLFC
|
0.090x |
|
Changhong Meiling Co Ltd B
SHE:200521
|
0.403x |
|
PC Jeweller Limited
NSE:PCJEWELLER
|
0.005x |
|
Real Brokerage Inc
NASDAQ:REAX
|
0.359x |
Annual Cash Flow Conversion Efficiency for Atea Pharmaceuticals Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Atea Pharmaceuticals Inc from 2018 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $275.43 Million | $-132.03 Million | -0.479x | -55.26% |
| 2024-12-31 | $438.87 Million | $-135.50 Million | -0.309x | -100.73% |
| 2023-12-31 | $555.19 Million | $-85.39 Million | -0.154x | +18.56% |
| 2022-12-31 | $640.57 Million | $-120.98 Million | -0.189x | -54.14% |
| 2021-12-31 | $710.08 Million | $-87.00 Million | -0.123x | -122.62% |
| 2020-12-31 | $547.80 Million | $296.73 Million | 0.542x | +109.55% |
| 2019-12-31 | $-49.57 Million | $-12.81 Million | 0.258x | +18.20% |
| 2018-12-31 | $-36.16 Million | $-7.91 Million | 0.219x | -- |